Study on Edoxaban for Patients with Atrial Fibrillation and Coronary Syndrome Undergoing PCI

3 1 1 1

What is this study about?

This clinical trial is focused on patients with atrial fibrillation, a condition where the heart beats irregularly, and those experiencing acute coronary syndrome or chronic coronary syndrome, which are types of heart problems. The study is investigating the use of a medication called Lixiana, which contains the active substance edoxaban. This medication is available in two forms: 30 mg and 60 mg film-coated tablets. The purpose of the study is to find the best way to prevent blood clots in these patients, especially after they have undergone a procedure called percutaneous coronary intervention (PCI), which is used to open blocked heart arteries.

Participants in the study will be given either the standard treatment or a new treatment strategy involving Lixiana. The study will compare the safety and effectiveness of these treatments by looking at the risk of bleeding and the occurrence of heart-related events like heart attacks or strokes. The study will last for several weeks, with follow-ups to check on the participants’ health and any side effects they might experience.

The trial aims to provide valuable information on how to best manage patients with these heart conditions, ensuring they receive the safest and most effective treatment. The results will help doctors make informed decisions about using Lixiana in patients with atrial fibrillation and heart syndromes, especially after they have had a PCI procedure.

1 joining the study

Upon joining the study, you will be informed about the purpose and procedures of the trial. You will be asked to provide consent to participate.

You will undergo an initial assessment to confirm eligibility, which includes being at least 18 years old, having undergone a successful percutaneous coronary intervention (PCI), and having a history of or newly diagnosed atrial fibrillation or flutter.

2 medication administration

You will be assigned to receive either a 30-day dual antiplatelet therapy (DAPT) or standard therapy. The specific medications and dosages will be explained to you by the study team.

You will take Lixiana tablets, which contain the active substance edoxaban. The dosage will be either 30 mg or 60 mg, taken orally as directed by the study team.

3 follow-up visits

You will have follow-up visits scheduled at 6 weeks and 6 months after the PCI procedure. These visits are to monitor your health and assess the safety and effectiveness of the treatment.

During these visits, you will be evaluated for any bleeding events and other health outcomes such as heart attack, stroke, or stent-related issues.

4 end of participation

Your participation in the study will conclude after the final follow-up visit at 6 months. The study team will provide you with any necessary information regarding your health and future care.

You will be informed about the overall results of the study once it is completed and analyzed.

Who Can Join the Study?

  • Must be 18 years of age or older.
  • Must have had a successful PCI. (PCI stands for Percutaneous Coronary Intervention, a procedure to open blocked blood vessels in the heart.)
  • Must have a history of or newly diagnosed atrial fibrillation or flutter. (Atrial fibrillation or flutter is a condition where the heart beats irregularly.)
  • Must have a long-term need for OAC. (OAC stands for Oral Anticoagulation, which is medication to prevent blood clots.)

Who Cannot Join the Study?

  • Patients with atrial fibrillation (a condition where the heart beats irregularly) cannot participate.
  • Patients with acute coronary syndrome (a range of conditions associated with sudden, reduced blood flow to the heart) cannot participate.
  • Patients with chronic coronary syndrome (a condition where the heart’s blood supply is blocked or reduced over time) cannot participate.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Azienda Ospedaliero Universitaria Careggi Florence Italy
Zuyderland Medisch Centrum Stichting Geleen The Netherlands
Katholieke Universiteit te Leuven Leuven Belgium
Stichting OLVG Amsterdam The Netherlands
Algemeen Stedelijk Ziekenhuis Campus Aalst Aalst Belgium

Other Sites

Site Name City Country Status
Catharina Ziekenhuis Stichting Eindhoven The Netherlands
St. Antonius Ziekenhuis Nieuwegein The Netherlands
Jan Yperman Ziekenhuis Ieper Belgium
Ziekenhuis Oost Limburg Genk Belgium
Isala Klinieken Stichting Zwolle The Netherlands
Centre Hospitalier Regional De La Citadelle Liege Belgium
Hospital Santa Maria Della Misericordia Perugia Italy
Stichting Viecuri Medisch Centrum voor Noord-Limburg Venlo The Netherlands
Medisch Spectrum Twente Enschede The Netherlands
HUmani Charleroi Belgium
Stichting Treant Ziekenhuiszorg Emmen The Netherlands
Haga Hospital Hague The Netherlands
Universitair Medisch Centrum Utrecht Utrecht The Netherlands
Azienda Unita Sanitaria Locale Di Bologna Bologna Italy
Universita’ Di Pisa Pisa Italy
Azienda USL Toscana Centro Prato Italy
CHC MontLegia Liege Belgium
Azienda Ospedaliero-Universitaria Maggiore Della Carita Novara Italy
Azienda Unita Sanitaria Locale Della Romagna Faenza Italy
Noordwest Ziekenhuisgroep Stichting Alkmaar The Netherlands
Vrije Universiteit Brussel Jette Belgium
Algemeen Ziekenhuis Delta Roeselare Belgium
Tergooiziekenhuizen Hilversum The Netherlands
Roskilde University Roskilde Denmark
Az Maria Middelares Gent Gent Belgium
Algemeen Ziekenhuis Groeninge Kortrijk Belgium
Elisabeth-Tweesteden Ziekenhuis Tilburg The Netherlands
Zealand University Hospital Koege Denmark
Ospedale “Morgagni – Pierantoni” di Forlì Forli' Italy
Aflcqhlik Uxl Amsterdam The Netherlands
Ldaav Upmcwvxivbdc Mztehny Cdizxye (nufsw Leiden The Netherlands
Utgoqnempm Hxaxbflo Or Pwdbv Parma Italy
Stny Apxyem Hjyvhdhd La Spezia Italy
Oljzxrfb Ms Btpquicj Cesena Italy
Rmqlemg Tbsdbettjrtzm Myvtsxql Bsgc Nijmegen The Netherlands
Aqziyj Uvfazhnvgo Hobxrxzj Aarhus Denmark
Adypbqf Ufz Iwkbl Dq Rngcof Ezowdd Reggio Emilia Italy
Urtvwdiexv Or Adisniw Edegem Belgium
Iwnkiz Bonheiden Belgium

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Belgium Belgium
Recruiting
25.11.2022
Denmark Denmark
Recruiting
25.11.2022
Italy Italy
Recruiting
25.11.2022
The Netherlands The Netherlands
Recruiting
25.11.2022

Trial locations

DAPT is a therapy that involves taking two medications together to prevent blood clots. This therapy is often used for people who have had a heart procedure called percutaneous coronary intervention (PCI) or who have a condition called atrial fibrillation (AF). The goal of DAPT is to reduce the risk of heart attacks or strokes by keeping the blood flowing smoothly through the arteries.

Atrial fibrillation – Atrial fibrillation is a heart condition characterized by an irregular and often rapid heart rate. It occurs when the upper chambers of the heart (atria) beat out of coordination with the lower chambers (ventricles). This can lead to poor blood flow and may cause symptoms such as heart palpitations, shortness of breath, and fatigue. Over time, atrial fibrillation can lead to complications like blood clots and heart failure. The condition can be intermittent or persistent, with episodes that may last from minutes to hours or even longer. It often requires ongoing monitoring to manage its progression.

Acute coronary syndrome – Acute coronary syndrome is a term used to describe a range of conditions associated with sudden, reduced blood flow to the heart. It includes situations where the heart muscle is at risk of damage due to insufficient oxygen supply. This condition often presents with chest pain or discomfort, which may radiate to other parts of the body. The progression can lead to more severe heart problems, such as a heart attack, if not addressed promptly. It is typically a result of the buildup of fatty deposits in and on the walls of coronary arteries. The condition requires immediate medical attention to prevent further heart damage.

Chronic coronary syndrome – Chronic coronary syndrome refers to a group of conditions that result from long-term reduction in blood flow to the heart muscle. It is often caused by the gradual buildup of plaque in the coronary arteries, leading to narrowed or blocked arteries. This can cause symptoms like chest pain or discomfort, especially during physical activity or stress. Over time, the reduced blood flow can weaken the heart muscle and lead to heart failure. The condition is typically stable but can become unstable if the plaque ruptures or if a blood clot forms. Management focuses on preventing progression and maintaining heart health.

Trial ID:
2022-502140-13-00
Trial Phase:
Therapeutic confirmatory (Phase III)

Other Trials to Consider

  • A Study to Test How Well PKN605 Works and How Safe It Is in Patients with Atrial Fibrillation

    Recruiting

    2 1
    Germany The Netherlands
  • Study of the efficacy and safety of inclisiran and a drug combination in patients with acute coronary syndrome

    Recruiting

    3 1 1
    France Germany Hungary Poland Spain